

11-25-05

CASE 10116 NP

IFW

NOV 28 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304409933US

Express Mail Label Number

November 23, 2005

Date of Deposit

O I P E

CANCELED

PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
GLUNZ ET AL.

APPLICATION NO: 10/775,923

CONFIRMATION NO. 1399

FILED: 02/10/2004

FOR: PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this
application and indicate that each reference was considered by returning a copy of the initialed PTO
1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791
Date: November 23, 2005


Jing G. Sun, Ph.D.
Agent for Applicants
Reg. No. 45,914



CASE10116 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV304409933US Express Mail Label Number	NOV 23 2005 November 23, 2005 Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
IN RE APPLICATION OF
GLUNZ ET AL.
APPLICATION NO: 10/775,923 CONFIRMATION NO.: 1399
FILED: 02/10/2004
FOR: PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:



Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791
Date: November 23, 2005


Jing G. Sun, Ph.D.
Agent for Applicants
Reg. No. 45,914



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/775923
Filing Date	02/10/2004
First Named Inventor	PETER GLUNZ
Art Unit	1625
Examiner Name	AULAKH, CHARANJIT
Attorney Docket Number	10116 NP

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Stedman's Medical Dictionary, 27 th Edition Illustrated in Color, Lippincott Williams & Wilkins, 1999, pp.1711, 1831, 1832.	
	AB	Dorland's Illustrated Medical Dictionary, 29 th Edition, W.B. Saunders Company, 2000, pp. 1836, 1837.	
	AC	Robbins Pathologic Basis of Disease, Sixth Edition, W. B. Saunders Company, 1999, pp. 113-138.	
	AD	Hurst's The Heart, 10 th Edition, 2001, pp.1373-1384.	
	AE	Harrison's Principles of Internal Medicine, 14 th Edition, Volume 2, 1998, pp.2325-2348.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/775923
Filing Date	02/10/2004
First Named Inventor	PETER GLUNZ
Art Unit	1625
Examiner Name	AULAKH, CHARANJIT
Attorney Docket Number	10116 NP

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Stedman's Medical Dictionary, 27 th Edition Illustrated in Color, Lippincott Williams & Wilkins, 1999, pp.1711, 1831, 1832.	
	AB	Dorland's Illustrated Medical Dictionary, 29 th Edition, W.B. Saunders Company, 2000, pp. 1836, 1837.	
	AC	Robbins Pathologic Basis of Disease, Sixth Edition, W. B. Saunders Company, 1999, pp. 113-138.	
	AD	Hurst's The Heart, 10 th Edition, 2001, pp.1373-1384.	
	AE	Harrison's Principles of Internal Medicine, 14 th Edition, Volume 2, 1998, pp.2325-2348.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant